MedDataX Logo

Transversus Abdominis Plane Block For Renal Transplant Recipients

NCT ID: NCT00905957

Last Updated: 2022-06-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of a local anaesthetic injection in the plane between the abdominal muscles in reducing the amount of pain relief required after surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet

NCT01273506

Healthy Volunteer
COMPLETED PHASE1

A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet

NCT01900587

Healthy
COMPLETED PHASE1

An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants

NCT01124604

Pain Low Back Pain Back Pain +1 more
COMPLETED PHASE2

A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers

NCT01309425

Healthy Volunteer
COMPLETED PHASE1

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

NCT00486811

Pain Knee Osteoarthritis
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to evaluate the efficacy of transversus abdominis plane block in reducing the morphine requirements after renal transplantation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Disorder Related to Renal Transplantation Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transversus abdominis plane (TAP) Group

Patients will receive a TAP block using a local anaesthetic agent after induction of anaesthesia

Group Type ACTIVE_COMPARATOR

TAP block

Intervention Type PROCEDURE

TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group

Control Group

Patients will receive a TAP block using a placebo after induction of anaesthesia

Group Type PLACEBO_COMPARATOR

TAP block with placebo

Intervention Type PROCEDURE

TAP block using a placebo after induction of anaesthesia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAP block

TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group

Intervention Type PROCEDURE

TAP block with placebo

TAP block using a placebo after induction of anaesthesia

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* renal transplant recipients
* 18 to 75 years

Exclusion Criteria

* allergy to local anaesthetics
* chronic pain
* refusal
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Liverpool University Hospitals NHS Foundation Trust

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Liverpool and Broadgreen University Hospitals

Liverpool, Merseyside, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Gulyam Kuruba SM, Mukhtar K, Singh SK. A randomised controlled trial of ultrasound-guided transversus abdominis plane block for renal transplantation. Anaesthesia. 2014 Nov;69(11):1222-6. doi: 10.1111/anae.12704. Epub 2014 Jun 28.

Reference Type DERIVED
PMID: 24974901 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3818

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain
NCT00449176 COMPLETED PHASE3
Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain
NCT00594516 COMPLETED PHASE3
An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)
NCT01631513 WITHDRAWN PHASE4
A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet
NCT01273532 COMPLETED PHASE1
A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine
NCT00505414 TERMINATED PHASE3
Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis
NCT00745069 COMPLETED PHASE2
Tapentadol (CG5503)
NCT00421928 COMPLETED PHASE3
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
NCT00472303 COMPLETED PHASE3
A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety
NCT00364533 TERMINATED PHASE3
Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty
NCT03351517 COMPLETED NA
Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID: 855509)
NCT00469053 TERMINATED PHASE1
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
NCT00487435 COMPLETED PHASE3
A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects
NCT02019485 COMPLETED PHASE1
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
NCT00983385 COMPLETED PHASE3
Tapentadol in Chronic Malignant Tumour Related Pain
NCT01264887 TERMINATED PHASE3
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic
NCT00983073 COMPLETED PHASE3
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
NCT00986180 COMPLETED PHASE3
A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain
NCT00364546 COMPLETED PHASE3
Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans
NCT01500317 COMPLETED PHASE4
A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery
NCT00361582 COMPLETED PHASE3
A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain
NCT02151682 COMPLETED PHASE2/PHASE3
A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants
NCT01981278 COMPLETED PHASE1
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
NCT00784277 COMPLETED PHASE3
Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants
NCT00805142 COMPLETED PHASE2
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.
NCT00982280 TERMINATED PHASE3